Who is sponsoring NCT00675688?

NCT00675688 is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

What drugs are being tested in NCT00675688?

Interventions in NCT00675688: Bazedoxifene/Conjugate Estrogens (CE), Raloxifene, Placebo.

What condition does NCT00675688 study?

NCT00675688 studies Endometrial Hyperplasia, Osteoporosis.

Is NCT00675688 still recruiting?

NCT00675688 is currently completed. Last updated 9 May 2008.

Last reviewed 2008-05-09 · How we verify

NCT00675688

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Double-Blind, Randomized, Placebo- and Active-Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women

Completed Phase 3 Last updated 9 May 2008

What this trial tests

Phase 3 trial testing Bazedoxifene/Conjugate Estrogens (CE) in Endometrial Hyperplasia in 3,544 participants. Completed in 1 January 2006.

Timeline

1 April 2002

Primary endpoint
1 January 2006

1 January 2006

Quick facts

Lead sponsor	Wyeth is now a wholly owned subsidiary of Pfizer
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	3,544
Start date	1 April 2002
Primary completion	1 January 2006
Estimated completion	1 January 2006

Drugs / interventions tested

Bazedoxifene/Conjugate Estrogens (CE) — full drug profile →
Raloxifene (RALOXIFENE) — full drug profile →
Placebo

Conditions studied

Endometrial Hyperplasia — all drugs for Endometrial Hyperplasia →
Osteoporosis — all drugs for Osteoporosis →

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer — full company profile →

Who can join

Adults 40 to 75, female only, with Endometrial Hyperplasia or Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To evaluate the effects of Bazedoxifene/Conjugate Estrogens (CE) combinations on the incidence of endometrial hyperplasia in postmenopausal women.
Time frame: one year

Sponsor's own description

The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
Archer DF, Freeman EW, Komm BS, Ryan KA, et al · · 2016 · cited 5× · PMID 27676118 · DOI 10.1089/jwh.2015.5558
Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene.
Kagan R, Goldstein SR, Pickar JH, Komm BS. · · 2016 · cited 5× · PMID 27103814 · DOI 10.2147/tcrm.s63833

Verify or expand the search:

Other recruiting trials for Endometrial Hyperplasia

Currently open trials in the same condition.

NCT06904274 — Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months · Phase 3 · recruiting
NCT07077876 — Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Tre · recruiting
NCT05903131 — Uterine Preservation Via Lifestyle Transformation · Phase 2 · recruiting
NCT06501846 — Pipelle® Under Ultrasound Guidance (PUG) to Investigate Post-menopausal Bleeding. · NA · recruiting
NCT06417736 — Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women · NA · recruiting

Other Wyeth is now a wholly owned subsidiary of Pfizer trials

Trials by the same sponsor.

NCT00909688 — Study to Evaluate Whether BLI-489 Can be Safely Tolerated by Healthy Subjects Given Multiple Doses · Phase 1 · completed
NCT00853749 — Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine · Phase 3 · completed
NCT00894634 — Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents · Phase 1 · completed
NCT00854009 — Study Evaluating Single Doses of BLI-489 in Healthy Japanese Male Subjects · Phase 1 · completed
NCT00837837 — Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00675688 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wyeth is now a wholly owned subsidiary of Pfizer
Last refreshed: 9 May 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00675688.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing